Replies to post #725 on Trius Therapeutics, Inc. (TSRX)

[TRUISM]

(b) one non-transferrable contingent value right for each share of Trius common stock, which represents the contractual right to receive up to $2.00 per share upon the achievement of certain milestones.

It seems that they want to give a value right currently but things are always subject to change,until the actual deal is finalized.


Take Care and God Bless....God Bless Us All.


Truth4Once

[noretreat]

My take: The 13.50 will come when the acquisition closes. Date unknown. Stock will trade up until closing so you can get out anytime. It will be interesting to see how the market values the potential milestone payment. The "up to $2" will not come until 2017, since it is based on 2016 sales of Tedizolid. Whether that is strictly calendar year, or CBST fiscal year (if different) is an open question.